drugset
drugset / Trial / NCT02323334

A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease

NCT02323334 ↗

Phase 1 Completed 94 enrolled Eli Lilly and Company
RandomizedSingle-groupDouble-blindBasic science

Summary

This study involves single and multiple doses of LY3202626 and will evaluate the effects of LY3202626 on the body. There will be 4 parts to this study. In Parts A and B, single increasing doses of LY3202626 will be given in capsule form. Part A will also include itraconazole given orally as a solution. Part A will last approximately 8-12 weeks. Part B will last approximately 5-6 weeks. In Parts C and D, participants will be dosed multiple days with the study drug. Part C will last approximately 11-14 weeks. Part D will last approximately 11-14 weeks and participants must have Alzheimer's Disease. Participants may only enroll in one part.

Timeline

Start
2014-12
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg Oral
Subject LY3202626 Unknown 0.1 mg Oral
Subject LY3202626 Unknown 0.4 mg Oral
Subject LY3202626 Unknown 1 mg Oral
Subject LY3202626 Unknown 1.6 mg Oral
Subject LY3202626 Unknown 5 mg Oral
Subject LY3202626 Unknown 6 mg Oral
Subject LY3202626 Unknown 10 mg Oral
Subject LY3202626 Unknown 15 mg Oral
Subject LY3202626 Unknown 26 mg Oral
Subject LY3202626 Unknown 45 mg Oral

Indications

Alzheimer disease